Stanford’s Avastin Study is Complete!

Cure HHT is excited to announce that “A Randomized Controlled Trial of Bevacizumab for HHT-Related Epistaxis” (aka “Avastin Trial”) conducted at Stanford University recruited its last patient on February 5, 2019!

THANK YOU to the 40 HHT patients who participated in the Avastin trial, many of whom traveled across the country to Palo Alto, California, and to the generous donor who established a travel reimbursement fund for those who needed financial assistance to make the journey!

Many patients with HHT suffer from recurrent, profound nose bleeds (epistaxis), which can require multiple blood transfusions, iron treatments, and trips to the operating room.

One possible way to reduce nose bleeds in HHT is by blocking the growth of the abnormal blood vessels in the nose using a medicine called Avastin (bevacizumab). This medicine has been studied in HHT patients with promising results as a safe an effective way to improve nasal bleeding.

This study’s aim was to evaluate the effectiveness and cost savings of using Avastin injection versus saline placebo in patients with HHT who also underwent cauterization surgery.

The preliminary results of this clinical trial will be presented in Puerto Rico this June at the 2019 International Scientific Conference.